JMP Securities analyst Jonathan Wolleben has reiterated their bullish stance on BCRX stock, giving a Buy rating today.
Jonathan Wolleben has given his Buy rating due to a combination of factors including BioCryst’s increased revenue guidance for Orladeyo, which is now expected to reach between $535 million and $550 million. This adjustment is attributed to improved reimbursement conditions, particularly within the Medicare population, which should maintain patient adherence to the treatment. Additionally, the company is on track to submit a supplemental NDA for pediatric HAE patients, which management believes could represent a $100 million opportunity.
Furthermore, BioCryst is poised for full-year profitability by 2026, a notable achievement within the small to mid-cap biotech sector. The stock is currently trading at an attractive valuation, approximately 3.5 times the midpoint of the new 2025 revenue guidance. Upcoming pipeline developments, such as data releases for BCX17225 in Netherton syndrome and avoralstat in diabetic macular edema, are anticipated to provide further upside to the company’s valuation. These factors collectively underpin Wolleben’s confidence in BioCryst’s growth prospects.
In another report released today, TD Cowen also maintained a Buy rating on the stock with a $20.00 price target.